Search

everythinglearnresearchcommunity

for

Search:↓

Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.

Hyperandrogenism does not affect the quality of blastocysts in PCOS patients undergoing IVF.

Macrophage activation syndrome can be a deadly first sign of systemic lupus erythematosus.

The conclusion is that lifestyle changes and weight loss are first-line treatments for infertility due to anovulation, with various medications and assisted reproductive technologies as additional options.

American men are older, more obese, and have longer infertility than Canadian men.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

Testing basal 17-HP levels is a good way to screen for nonclassic adrenal hyperplasia in women with high androgen levels.

Different types of polycystic ovary syndrome (PCOS) have varying severity, with Type I being the most severe and common.

Most women with PCOS have high levels of male hormones, and free testosterone is the best marker for this.

Flutamide may slightly improve hair loss in women, but finasteride does not work.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Diane 35 plus finasteride is more effective for treating hirsutism.

Women with PCOS are more likely to have sleep apnea, mainly if they are obese.

Flutamide reduces hair growth better but has more side effects.

Diane 35 plus finasteride is more effective in reducing hair growth and androgen levels, but may decrease libido.

Women with PCOS often have hair loss, which is linked to acne or excess body hair but not to worse hormone or metabolic issues.

There's no significant link between the D19S884 marker at the insulin receptor gene and polycystic ovary syndrome.

Insulin resistance is significantly linked to a higher risk of depression in women with PCOS.

Insulin resistance might not be enough to worsen blood vessel function in young, nonobese women with polycystic ovary syndrome.

Longer CAG repeat lengths in the androgen receptor gene are linked to higher testosterone levels in women with PCOS.

Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

Finasteride and flutamide both reduce hair growth, but finasteride has fewer side effects.

Finasteride can cause serious side effects in some men, needing more research for treatment.

Young women with PCOS have a higher risk of high blood pressure and metabolic syndrome, but these risks may decrease after age 40.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.